AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6104384 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (500 micrograms/h) with active fungal lipase (150,000 E)
Number of subjects: 7
Study 6104384 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin infusion (500 micrograms/h) with placebo capsules
Number of subjects: 7
Study 31841475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial polychemotherapy (IA PCT) prior to radiotherapy
Number of subjects: 280
Study 31841475 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic radiochemotherapy with polyplatilen
Number of subjects: 280
Study 31841475 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 280
Study 31841475 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction polychemotherapy with polyplatilen
Number of subjects: 280
Study 31841475 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiothermic personalisation
Number of subjects: 280
Study 31841475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial polychemotherapy followed by radiotherapy
Number of subjects: 280
Study 28349328 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg alone
Number of subjects: 28
Study 28349328 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine FDC (with lamivudine and tenofovir disoproxil fumarate)
Number of subjects: 28
Study 26471136 — intervention group
Group type: EXPERIMENTAL
Intervention: Aut‐A
Number of subjects: 4
Study 26471136 — intervention group
Group type: EXPERIMENTAL
Intervention: Aut‐B
Number of subjects: 4
Study 26471136 — intervention group
Group type: COMPARATOR
Intervention: HC
Number of subjects: 4
Study 26471136 — intervention group
Group type: COMPARATOR
Intervention: MA
Number of subjects: 4
Study 24528997 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based inhaled corticosteroid treatment
Number of subjects: 74
Study 24528997 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 74
Study 22932809 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE
Number of subjects: 20
Study 22932809 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 20
Study 19121451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol monotherapy
Number of subjects: 845
Study 19121451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol plus diuretic
Number of subjects: 845
Study 19121451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol plus calcium channel blocker
Number of subjects: 845
Study 19121451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol plus other antihypertensive medication
Number of subjects: 845
Study 17303529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 43
Study 17303529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 15879354 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous methimazole (MMI) treatment
Number of subjects: 504
Study 15879354 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine treatment
Number of subjects: 504
Study 14704751 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral inferior oblique muscle myectomy
Number of subjects: 24
Study 14704751 — intervention group
Group type: COMPARATOR
Intervention: Standard recession for inferior oblique muscle overaction
Number of subjects: 24
Study 10658521 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended mastectomy with internal mammary node dissection
Number of subjects: 737
Study 10658521 — intervention group
Group type: COMPARATOR
Intervention: Halsted mastectomy
Number of subjects: 737
Study 8876348 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet combined with resistance training
Number of subjects: 20
Study 8876348 — intervention group
Group type: COMPARATOR
Intervention: Diet only (3,400 kJ/day)
Number of subjects: 20
Study 2065721 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ketanserin
Number of subjects: 20
Study 2065721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7158619 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertiveness training
Number of subjects: 343
Study 7158619 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 343
Study 7158619 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 343
Study 31644605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine
Number of subjects: 613
Study 28601335 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home box trainer (BT)
Number of subjects: 25
Study 28601335 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality simulator (VR)
Number of subjects: 25
Study 27023009 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab (anti-CD3 monoclonal antibody) administered subcutaneously
Number of subjects: 0
Study 27023009 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid treatment
Number of subjects: 0
Study 27023009 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis measures
Number of subjects: 0
Study 25062593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 50
Study 25062593 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 50
Study 22429859 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigated gold tip catheter
Number of subjects: 60
Study 22429859 — intervention group
Group type: COMPARATOR
Intervention: Irrigated platinum tip catheter
Number of subjects: 60
Study 19369188 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 11
Study 19369188 — intervention group
Group type: COMPARATOR
Intervention: Park sham device
Number of subjects: 11
Study 18204132 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-fine HFA beclomethasone dipropionate (HFA-BDP) 400 microg twice daily for 7 days followed by 200 microg twice daily for 4 days
Number of subjects: 72
Study 18204132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 15785378 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan treatment for 3 months
Number of subjects: 20
Study 15785378 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 individuals after renal donation)
Number of subjects: 20
Study 12218749 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month whole body vibration training (4 min/day, 3-5 times a week)
Number of subjects: 56
Study 12218749 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 9858270 — intervention group
Group type: EXPERIMENTAL
Intervention: Brenner tumors on T2-weighted images
Number of subjects: 21
Study 9858270 — intervention group
Group type: COMPARATOR
Intervention: Other ovarian tumors on T2-weighted images
Number of subjects: 21
Study 8585887 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 30 mg dose of Centchroman (group I, n = 8)
Number of subjects: 13
Study 8585887 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Centchroman twice a week for twelve weeks (group II, n = 5)
Number of subjects: 13
Study 8585887 — intervention group
Group type: COMPARATOR
Intervention: Both dosing groups (group I and group II)
Number of subjects: 13
Study 2162275 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (IV infusion)
Number of subjects: 6
Study 2162275 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide histidine valine (IV infusion)
Number of subjects: 6
Study 2162275 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide histidine methionine (IV infusion)
Number of subjects: 6
Study 2162275 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (intra-arterial infusion)
Number of subjects: 6
Study 2162275 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide histidine valine (intra-arterial infusion)
Number of subjects: 6
Study 2162275 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide, peptide histidine methionine, peptide histidine valine (IV infusion)
Number of subjects: 6
Study 2162275 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide histidine valine
Number of subjects: 6
Study 375053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic vincristine‐streptonigrin alternating every 2 weeks with cyclophosphamide‐prednisone up to 155 days
Number of subjects: 203
Study 375053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with the same 4 drugs taken singly up to 182 days
Number of subjects: 203
Study 375053 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine‐prednisone induction for 6 weeks followed by cyclophosphamide maintenance
Number of subjects: 203
Study 30999125 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and MFGM (Ex + MFGM)
Number of subjects: 126
Study 30999125 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and placebo (Ex + P)
Number of subjects: 126
Study 30999125 — intervention group
Group type: COMPARATOR
Intervention: MFGM
Number of subjects: 126
Study 30999125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 28372652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Number of subjects: 96
Study 28372652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Number of subjects: 96
Study 28372652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg
Number of subjects: 96
Study 28372652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 25936547 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based supportive intervention facilitated by a nurse
Number of subjects: 36
Study 23494802 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (1 g/day)
Number of subjects: 30
Study 23494802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21338986 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 80
Study 21338986 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 80
Study 19720791 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (20% fat, 60% carbohydrate)
Number of subjects: 24
Study 19720791 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet (60% fat, 20% carbohydrate)
Number of subjects: 24
Study 19720791 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 24
Study 19720791 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet
Number of subjects: 24
Study 17230585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat beta-glucan enriched fecal water
Number of subjects: 6
Study 15182511 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen enriched air (24.30 +/- 0.88% oxygen)
Number of subjects: 12
Study 15182511 — intervention group
Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 12
Study 11843243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 797
Study 11843243 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 797
Study 9777083 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal morphine 25 micrograms.kg‐1
Number of subjects: 52
Study 9777083 — intervention group
Group type: COMPARATOR
Intervention: Caudal morphine 50 micrograms.kg‐1
Number of subjects: 52
Study 7889959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg q. 12 hours
Number of subjects: 702
Study 7889959 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 500 mg q. eight hours
Number of subjects: 702
Study 7889959 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil 500 mg q. 12 hours
Number of subjects: 702
Study 7889959 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate 500 mg q. eight hours
Number of subjects: 702
Study 3323023 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 18
Study 3323023 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 18
Study 3323023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29595510 — intervention group
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE (10 μg ID93 + 2 μg GLA-SE)
Number of subjects: 66
Study 29595510 — intervention group
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE (2 μg ID93 + 2 μg GLA-SE)
Number of subjects: 66
Study 29595510 — intervention group
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE (10 μg ID93 + 5 μg GLA-SE)
Number of subjects: 66
Study 29595510 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 66
Study 27709734 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health intervention for siblings
Number of subjects: 12
Study 25704662 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon colonoscopy
Number of subjects: 126
Study 25704662 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 126
Study 23906657 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (sugarless gum, chewed three times for 30 min each from the first postoperative morning until the first passage of flatus)
Number of subjects: 149
Study 23906657 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 149
Study 20951018 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE-active programme (6-month compulsory period: 3 sessions/week; 5-month optional period: 2 sessions/week)
Number of subjects: 153
Study 20951018 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE-active programme
Number of subjects: 153
Study 20951018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 153
Study 18510625 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day oral sodium phosphate solution (NaP solution) (1 mL/kg/day, maximum 90 mL in two divided doses; regimen A)
Number of subjects: 48
Study 18510625 — intervention group
Group type: COMPARATOR
Intervention: 3-day magnesium citrate (4 mL/kg/day x 3 days, maximum 237 mL, followed by an enema; regimen B)
Number of subjects: 48
Study 18510625 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day oral sodium phosphate solution (NaP solution) (regimen A)
Number of subjects: 48
Study 18510625 — intervention group
Group type: COMPARATOR
Intervention: 3-day magnesium citrate (regimen B)
Number of subjects: 48
Study 18510625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 48
Study 16779923 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-pubertal (EP) males
Number of subjects: 0
Study 16779923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-pubertal (MP) males
Number of subjects: 0
Study 16779923 — intervention group
Group type: COMPARATOR
Intervention: Late-pubertal (LP) males
Number of subjects: 0
Study 16779923 — intervention group
Group type: COMPARATOR
Intervention: Young-adult (YA) males
Number of subjects: 0
Study 14632796 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based treatment guidelines for pemphigus vulgaris
Number of subjects: 0
Study 14719289 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Oldenlandis Mixture
Number of subjects: 86
Study 14719289 — intervention group
Group type: COMPARATOR
Intervention: Dang Gui Ku Shen Wan (Control)
Number of subjects: 86
Study 10220209 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital imaging technique
Number of subjects: 18
Study 10220209 — intervention group
Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 18
Study 8615060 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol treatment for 6 weeks
Number of subjects: 26
Study 8615060 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol treatment
Number of subjects: 26
Study 2671058 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 42
Study 2671058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 1091149 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term antibiotic prophylaxis regimen with 3 Gm. of cephaloridine in divided doses on the day of operation
Number of subjects: 100
Study 1091149 — intervention group
Group type: COMPARATOR
Intervention: Long-term antibiotic prophylaxis regimen with oral cephalexin postoperatively
Number of subjects: 100
Study 31754826 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheimpflug camera (Pentacam)
Number of subjects: 44
Study 31754826 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior segment optical coherence tomography (AS-OCT)
Number of subjects: 44
Study 31754826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound pachymetry (USP)
Number of subjects: 44
Study 31754826 — intervention group
Group type: COMPARATOR
Intervention: Comparison of devices in < 600 μm group
Number of subjects: 44
Study 27882592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopic stone surgery with JJ catheterisation
Number of subjects: 72
Study 27882592 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy males)
Number of subjects: 72
Study 25826715 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Safety Screener-2
Number of subjects: 951
Study 25826715 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Safety Screener-3
Number of subjects: 951
Study 25826715 — intervention group
Group type: COMPARATOR
Intervention: Beck Scale for Suicide Ideation (BSSI)
Number of subjects: 951
Study 23673884 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV intervention
Number of subjects: 848
Study 21842168 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG neurofeedback (NF)
Number of subjects: 35
Study 21842168 — intervention group
Group type: COMPARATOR
Intervention: EMG biofeedback (BF)
Number of subjects: 35
Study 19380134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) abciximab administration
Number of subjects: 50
Study 19380134 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) abciximab administration
Number of subjects: 50
Study 18389773 — intervention group
Group type: EXPERIMENTAL
Intervention: Special diet consisting of 15 ml/day balsamic vinegar from apples and honey, seabuckthorn berry, rosemary, sage, and basil extracts, 150 g/day whole wheat bread with 2.5% VITAPAN, 15 ml/day grape seed extract rich in polyphenols (gr. 1)
Number of subjects: 34
Study 18389773 — intervention group
Group type: COMPARATOR
Intervention: Control group (gr. 2)
Number of subjects: 34
Study 18389773 — intervention group
Group type: EXPERIMENTAL
Intervention: Special diet (gr. 1)
Number of subjects: 34
Study 15336619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of alendronate daily + exercise (Al+Ex+)
Number of subjects: 102
Study 15336619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg alendronate daily (Al+Ex‐)
Number of subjects: 102
Study 15336619 — intervention group
Group type: COMPARATOR
Intervention: Placebo + exercise (Al‐Ex+)
Number of subjects: 102
Study 15336619 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Al‐Ex‐)
Number of subjects: 102
Study 11519552 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium suspension with dynamic viscosity of 320 cPs (G1)
Number of subjects: 161
Study 11519552 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium suspension with dynamic viscosity of 2500 cPs (G2)
Number of subjects: 161
Study 11519552 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium suspension with dynamic viscosity of 3200 cPs (G3)
Number of subjects: 161
Study 11519552 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with standard barium suspension viscosity of 280 cPs
Number of subjects: 161
Study 11519552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium members in paired groups
Number of subjects: 161
Study 9781930 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril, 4 mg o.d. for 6 weeks
Number of subjects: 28
Study 9781930 — intervention group
Group type: COMPARATOR
Intervention: Losartan, 50 mg o.d. for 6 weeks
Number of subjects: 28
Study 7828343 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion (5 micrograms/kg/min i.v.) for 83-296 hours
Number of subjects: 9
Study 3280759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral posterior approach to the ilium
Number of subjects: 100
Study 3280759 — intervention group
Group type: COMPARATOR
Intervention: Lateral anterior approach to the ilium
Number of subjects: 100
Study 31839368 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 52
Study 31839368 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine HCl
Number of subjects: 52
Study 31162530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-weight reduction guided by lung ultrasound
Number of subjects: 71
Study 31162530 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment (control)
Number of subjects: 71
Study 27771359 — intervention group
Group type: EXPERIMENTAL
Intervention: Active IFC + Pilates
Number of subjects: 148
Study 27771359 — intervention group
Group type: COMPARATOR
Intervention: Placebo IFC + Pilates
Number of subjects: 148
Study 26261007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir (n=25)
Number of subjects: 126
Study 26261007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir with ribavirin (n=26)
Number of subjects: 126
Study 26261007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir with ribavirin (n=50)
Number of subjects: 126
Study 23421578 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention program using abdominal palpation of Leopold's Maneuvers
Number of subjects: 108
Study 23421578 — intervention group
Group type: COMPARATOR
Intervention: Ordinary health-related advice
Number of subjects: 108
Study 20837369 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar (600 μg/day)
Number of subjects: 174
Study 20837369 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 174
Study 19269691 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 797
Study 19269691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 797
Study 19269691 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram and Nortriptyline
Number of subjects: 797
Study 16954961 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-predominant study formula (protein/energy ratio: 1.8 g/100 kcal)
Number of subjects: 162